AstraZeneca: Tagrisso Plus Chemotherapy Demonstrated Strong Improvement in Progression-Free Survival for Patients With EGFR-Mutated Advanced Lung Cancer in Flaura2 Phase III Trial
May 18, 2023
May 18, 2023
WILMINGTON, Delaware, May 18 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca's TAGRISSO(R) (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal . . .
Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca's TAGRISSO(R) (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal . . .